High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

por Qiao, G-B, Wu, Y-L, Yang, X-N, Zhong, W-Z, Xie, D, Guan, X-Y, Fischer, D, Kolberg, H-C, Kruger, S, Stuerzbecher, H-W
Publicado 2005

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

por Chen, R.-L., Chen, H.-J., Jiang, B.-Y., Zhang, X.-C., Zhou, Q., Tu, H.-Y., Zhong, W.-Z., Wu, Y.-L., Yang, J.-J.
Publicado 2017

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

por Yang, J J, Zhou, Q, Yan, H H, Zhang, X C, Chen, H J, Tu, H Y, Wang, Z, Xu, C R, Su, J, Wang, B C, Jiang, B Y, Bai, X Y, Zhong, W Z, Yang, X N, Wu, Y L
Publicado 2017